Tag Archives: Biopharmaceutical (TRBC level 5)

Brazil approved Pfizer’s COVID-19 shots, but none of them worked | Instant News


FILE PHOTOS: Pfizer-BioNTech vaccine bottle pictured at a vaccination center in Geneva, Switzerland, February 3, 2021. REUTERS / Denis Balibouse

SAO PAULO (Reuters) – Brazil has fully approved the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE, its health regulators said on Tuesday, although disagreements over a supply deal mean neither side can initiate an immunization program.

This is the first coronavirus injection to receive full approval in Brazil, said regulator Anvisa. The vaccine, developed by AstraZeneca and China Sinovac Biotech Ltd, is only approved for emergency use.

The agreement is good news for a country whose immunization campaign has been plagued by delays and political bickering. However, it is unclear if this will pave the way for a supply deal for the highly effective shoots that are being rolled out globally.

“We look forward to moving forward in our negotiations with the Brazilian government to support immunization of the country’s population,” said Pfizer Brazil boss Marta Diez in a statement, without providing further details.

Brazil’s Ministry of Health did not respond to a request for comment.

President Jair Bolsonaro has criticized the terms of the deal proposed by Pfizer, saying the deal was too burdensome because it freed US companies from potential liability for unforeseen problems. Pfizer said other countries, including Brazil’s Latin American neighbors, have agreed to the terms.

Reporting by Eduardo Simoes. Written by Gabriel Stargardter. Edited by Mark Potter and John Stonestreet

.



image source

Under pressure, Brazil’s health minister promised more injections of the COVID vaccine | Instant News


RIO DE JANEIRO, February 17 (Reuters) – Pressured by state governors over a shortage of coronavirus vaccines, Brazil’s health minister on Wednesday vowed to mobilize 11.3 million injections by the end of the month, but including doses that have not been given. confirmed.

With vaccination campaigns halted in recent days in major cities like Rio de Janeiro and Salvador due to a lack of injections, Minister Eduardo Pazuello has faced increasing criticism from governors and mayors over the inoculation program.

After Pazuello met with the governor on Wednesday afternoon, the ministry issued a statement saying 11.3 million doses would be available in February.

That figure includes the 9.3 million doses guaranteed by the Butantan institute in Sao Paulo through its partnership with China Sinovac Biotech Ltd, plus 2 million doses of the vaccine made by Britain’s AstraZeneca Plc, according to the statement.

However, delivery of AstraZeneca doses has not been confirmed by India where they were produced and they are still in negotiations with AstraZeneca, the Brazilian research institute Fiocruz, which is responsible for importing the vaccine, said in a separate statement.

The Ministry of Health did not immediately comment on the inclusion of an unsecured vaccine from AstraZeneca in its plans.

The AstraZeneca vaccine was originally planned to be the main pillar of Brazil’s national inoculation program, but so far most of the doses have come from Sinovac. (Reporting by Pedro Fonseca, written by Sabrina Valle, Editing by Rosalba O’Brien)

.



image source

Sinovac vaccine works on the British variant, South Africa – Brazilian Institute | Instant News


FILE PHOTO: A worker carries out a quality check at the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS / Thomas Peter / File Photo

SERRANA, Brazil (Reuters) – The COVID-19 vaccine developed by China’s Sinovac Biotech is effective against British and South African variants, Brazil’s vaccine partners said on Wednesday, citing test results in a Chinese trial.

“We have tested this vaccine in China against English and South African variants, with good results,” said Dimas Covas, head of the Butantan biomedical center in Sao Paulo who is leading domestic trials of the Chinese vaccine and supplying doses to Brazilian Health. Ministry.

Covas did not provide further details on how effective the vaccine was to prove against this strain.

Butantan is also testing a vaccine, known as CoronaVac, against a Brazilian variant of the virus that emerged in the city of Manaus, he said.

“Soon we will have results and we are very confident it will work,” Covas said.

Covas was speaking at a press conference in the small town of Serrana, in the interior of the state of Sao Paulo, where Butantan on Wednesday started a mass vaccination campaign aimed at injecting the entire adult population against COVID-19 to test whether it lowers infection rates. .

Covas said he expects CoronaVac to have an advantage over other vaccines because of the technology it uses – an inactive version of the coronavirus.

The efficacy of the Chinese vaccine against Brazilian strains will be particularly important for Brazil. The government has secured 100 million doses and made the vaccine the center of an inoculation campaign.

Covas’ comments came as several cities in Brazil, including the state capitals of Rio, Salvador and Cuiaba, have suspended new vaccinations because they ran out of doses.

Reporting by Leonardo Benassatto, written by Sabrina Valle; editing by Stephen Eisenhammer and Aurora Ellis

.



image source

Brazil gets the first active ingredient for the AstraZeneca vaccine from China | Instant News


RIO DE JANEIRO (Reuters) – Brazil’s first shipment of 88 liters of the active ingredient to make AstraZeneca’s COVID-19 vaccine arrived from China on Saturday, an important input for accelerating the country’s troubled vaccination program.

With the supplies flown to Rio de Janeiro by cargo plane, the Fiocruz biomedical center can start filling and completing 2.8 million doses. The federally-funded center expects to receive more material this month to make up a total of 15 million vaccine shots developed with the University of Oxford.

Fiocruz’s production line, which was originally scheduled to start production in December, has been idle due to delays in the first shipment of supplies from China.

The AstraZeneca Plc vaccine is a major pillar of Brazil’s national inoculation program and the federal government has ordered ingredients for Fiocruz to make up to 100 million injections.

To begin inoculating its 210 million population, Brazil initially relied on a Chinese vaccine developed by Sinovac Biotech Ltd and 2 million ready-to-use AstraZeneca injections imported from India last month.

Pfizer Inc filed an application on Friday for full regulatory approval in Brazil of a COVID-19 vaccine developed with BioNTech Se, the company said.

This is the second vaccine submitted for registration in Brazil. AstraZeneca submitted an application on January 29 for full regulatory approval of its vaccine.

President Jair Bolsonaro, who has said he will not take a COVID-19 shot, is under pressure after a slow and uneven vaccine rollout in Brazil, which is now facing a second wave of infections.

Bolsonaro has called the virus a “mild flu” but his government is facing increasing criticism for its handling of the world’s second-deadliest coronavirus outbreak that has killed more than 231,000 Brazilians.

Sao Paulo’s Butantan Biomedical Institute said on Saturday it had started refilling and depleting 8.6 million doses of a Sinovac vaccine called Coronavac with ingredients that arrived from China on Wednesday.

Butantan said it expects to receive another supply of ingredients on Wednesday to make up an additional 8.7 million doses.

Reporting by Sergio Queiroz, Written by Anthony Boadle; Edited by David Gregorio

.



image source

Brazil gets the first active ingredient for the AstraZeneca vaccine from China | Instant News


RIO DE JANEIRO (Reuters) – Brazil’s first shipment of 88 liters of the active ingredient to make AstraZeneca’s COVID-19 vaccine arrived from China on Saturday, an important input for accelerating the country’s troubled vaccination program.

With the supplies flown to Rio de Janeiro by cargo plane, the Fiocruz biomedical center can start filling and completing 2.8 million doses. The federally-funded center expects to receive more material this month to make up a total of 15 million vaccine shots developed with the University of Oxford.

Fiocruz’s production line, which was originally scheduled to start production in December, has been idle due to delays in the first shipment of supplies from China.

The AstraZeneca Plc vaccine is a major pillar of Brazil’s national inoculation program and the federal government has ordered ingredients for Fiocruz to make up to 100 million injections.

To begin inoculating its 210 million population, Brazil initially relied on a Chinese vaccine developed by Sinovac Biotech Ltd and 2 million ready-to-use AstraZeneca injections imported from India last month.

Pfizer Inc filed an application on Friday for full regulatory approval in Brazil of a COVID-19 vaccine developed with BioNTech Se, the company said.

This is the second vaccine submitted for registration in Brazil. AstraZeneca submitted an application on January 29 for full regulatory approval of its vaccine.

President Jair Bolsonaro, who has said he will not take a COVID-19 shot, is under pressure after a slow and uneven vaccine rollout in Brazil, which is now facing a second wave of infections.

Bolsonaro has called the virus a “mild flu” but his government is facing increasing criticism for its handling of the world’s second-deadliest coronavirus outbreak that has killed more than 231,000 Brazilians.

Sao Paulo’s Butantan Biomedical Institute said on Saturday it had started refilling and depleting 8.6 million doses of a Sinovac vaccine called Coronavac with ingredients that arrived from China on Wednesday.

Butantan said it expects to receive another supply of ingredients on Wednesday to make up an additional 8.7 million doses.

Reporting by Sergio Queiroz, Written by Anthony Boadle; Edited by David Gregorio

.



image source